With several contradictory reports on the efficacy of hydroxychloroquine (HCQ) on COVID-19, the Indian Council of Medical Research (ICMR) recommended its use for prophylaxis and treatment of mild cases during the first wave of the pandemic. Amidst all the controversies, there have been a few cases reported of significant methemoglobinemia and hemolysis in COVID-19 cases being treated with HCQ. The diagnosis of methemoglobinemia amidst this COVID-19 crisis is really challenging owing to similar clinical manifestations. We present a case series where methemoglobinemia was promptly detected and managed efficiently, resulting in the uneventful discharge of all three cases. This is to be understood that undiagnosed cases of methemoglobinemia can be potentially fatal due to hypoxic stress on the body. If the condition is not being detected timely, leading to dangerous levels of untreated methemoglobinemia may cause a case of fatality falsely attributed to COVID-19. However, when the HCQ is not being used for COVID-19 presently, still clinicians must know different drugs that can cause methemoglobinemia and should promptly intervene to avoid any catastrophe.
Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID–19: results of a randomized clinical trial. medRxiv 2020. DOI: 10.1101/2020.03.22.20040758. (Accessed 03/06/2021).
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID–19: Results of an open–label non–randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949
Indian Council for Medical Research. Recommendation for Empiric use of Hydroxychloroquine for Prophylaxis of SARS–CoV–2 Infection. Available from: https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22March_final_MM_V2.pdf(Accessed 12/06/2020) DOI: 10.1016/j.ijantimicag.2020.105949
Chatterjee P, Anand T, Singh KJ, et al. Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19. Indian J Med Res 2020;151(5):459–467. DOI: 10.4103/ijmr.IJMR_2234_20
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Available from: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 (Accessed 07/10/2020).
Available from: https://www.who.int/news/item/04-07-2020/WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 (Accessed 10/09/2020).
Naymagon L, Berwick S, Kessler A, et al. The emergence of methemoglobinemia amidst the COVID-19 pandemic. Am J Hematol 2020;95(8):E196–E197. DOI: 10.1002/ajh.25868
Beauverd Y, Adam Y, Assouline B, et al. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol 2020;105(3):357–359. DOI: 10.1111/ejh.13432
Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med 1999;34(5):646–656. DOI: 10.1016/s0196-0644(99)70167-8
Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med 1986;314(12):757–761. DOI: 10.1056/NEJM198603203141206
Belfield KD, Tichy EM. Review and drug therapy implications of glucose–6–phosphate dehydrogenase deficiency. Am J Health Syst Pharm 2018;75(3):97–104. DOI: 10.2146/ajhp160961
Badawi MA, Badawi MA, Wali SO, et al. Hereditary methemoglobinemia manifesting in adolescence. J Appl Hematol 2016;7(3):108–110. DOI: 10.4103/1658-5127.192983
Kedar PS, Gupta V, Warang P, et al. Novel mutation (R192C) in CYB5R3 gene causing NADH-cytochrome b5 reductase deficiency in eight Indian patients associated with autosomal recessive congenital methemoglobinemia type-I. Hematology 2018;23(8):567–573. DOI: 10.1080/10245332.2018.1444920
Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5(9):1036. DOI: 10.1001/jamacardio.2020.1834
Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and Torsade De Pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm 2020;17(9): 1425–1433. DOI: 10.1016/j.hrthm.2020.05.014
Agstam S, Yadav A, Kumar MP, et al. Hydroxychloroquine and QTc prolongation in patients with COVID-19: a systematic review and meta-analysis. Indian Pacing Electrophysiol J 2020;21(1):36–43. DOI: 10.1016/j.ipej.2020.10.002
Sridhar AR, Chatterjee NA, Saour B, et al. QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019. Heart Rhythm O2 2020;1(3):167–172. DOI: 10.1016/j.hroo.2020.06.002
Kumar MP, Mohindra R, Bhalla A, et al. System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. Expert Rev Anti Infect Ther 2021;19(10):1331–1339. DOI: 10.1080/14787210.2021.1909476
Naik SN. Glucose-6-phosphate dehydrogenase deficiency in India and its clinical significance. J Assoc Physicians India 1994;42(3): 229–234. PMID: 7860515.
Shihana F, Dawson AH, Dobbins T, et al. A bedside test for methaemoglobinemia improved antidote use in propanil poisoning. Clin Toxicol (Phila) 2016;54(7):576–580. DOI: 10.1080/15563650.2016.1177651
Khanal R, Karmacharya P, Pathak R, et al. Do all patients with acquired methemoglobinemia need treatment? A lesson learnt. J Community Hosp Intern Med Perspect 2015;5(5):29079. DOI: 10.3402/jchimp.v5.29079
Dasararaju R, Adamski J. Transfusion medicine illustrated: An unusual case of near-fatal hemolytic anemia treated with erythrocytapheresis and therapeutic plasma exchange. Transfusion 2015;55(3):475. DOI: 10.1111/trf.12857